| Document |
Document Title |
|
WO/2024/089159A1 |
The invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, pharmaceutical compositions comprising the compounds and methods for synthesising compounds according to formula I. This invention further...
|
|
WO/2024/089272A1 |
The present invention relates to the prevention and/or treatment of protein tyrosine kinase mediated diseases, in particular phosphatidylinositol 3-kinases (PI3Ks) mediated diseases. PI3Ks are well-known as oncology targets and several i...
|
|
WO/2024/091450A1 |
The present disclosure relates to compounds for treating cancer. The compounds may prevent conversion of non-stem cancer cells into cancer-initiating cells caused by radiation treatment.
|
|
WO/2024/092011A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2024/092185A1 |
Provided herein are compounds useful for treating a viral infection caused by polyomavirus, e.g., by inhibiting polyomavirus replication. Also provided are compositions and methods including the provided compounds.
|
|
WO/2024/091511A1 |
The present application relates to compounds of Formula (I), where R1, R2, X, Y, z1 and z2 are as define herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical compositions comprising...
|
|
WO/2024/092219A1 |
The present disclosure relates to novel compounds comprising self-hydrolyzing maleimide functional groups, salts of these compounds, pharmaceutically acceptable salts of these compounds, methods of making these compounds, and methods of ...
|
|
WO/2024/089683A1 |
Anticancer conjugates combining a DNA methylation agent and an anticancer drug are provided herein, as well as uses of the same in cancer treatment.
|
|
WO/2024/092009A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.
|
|
WO/2024/090485A1 |
The present invention provides a method for producing a fluorine-containing compound under relatively mild conditions by introducing a fluorine atom into a wide variety of oxygen-containing compounds having a ketone group, an aldehyde gr...
|
|
WO/2024/085386A1 |
It has been identified that an alkynyl amino acid ester derivative preparation method using a photocatalytic reaction, according to the present invention, is simple and enables a linear, cyclic or chiral alkynyl amino acid ester derivati...
|
|
WO/2024/086111A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2024/044098A3 |
This disclosure provides peptide based compounds, compositions, and methods to treat medical disordeds, such as complement-mediated disorders, including complement C1s-mediated disorders, such as acute antibody-mediated rejection, amyotr...
|
|
WO/2024/078614A1 |
Provided are an amino lipid compound for preparing a lipid nanoparticle for delivering an active ingredient and a preparation method therefor, a lipid nanoparticle and a pharmaceutical composition containing the amino lipid compound, and...
|
|
WO/2024/081762A1 |
Disclosed herein are substituted 5-membered ring molecules substituted with fluorinated benzyl groups and amino acid groups of formula (I), and derivatives thereof. The substituted 5-membered ring molecules have herbicidal activity and c...
|
|
WO/2024/079206A1 |
The present invention relates to crystalline form I and form II of (2S,5R)-5-(2- chlorophenyl)- 1-(2'-methoxy- [1,1 '-biphenyl] -4-carbonyl)pyrrolidine-2-carboxylic acid and preparation processes thereof.
|
|
WO/2024/079128A1 |
The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example, Z is representing a (II) X is representing a NR5R6 group wherein R5 and R6 are hydrogen, R1 is represe...
|
|
WO/2024/075760A1 |
The present invention addresses the problem of providing: a novel method for producing a N-acetyl-D-galactosamine ligand-oligonucleotide conjugate, particularly a novel method for producing a N-acetyl-D-galactosamine unit; and a novel in...
|
|
WO/2024/075825A1 |
The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity. The present invention pertains to a cyclopentane compound represented by formula (I) or a pharmacologically acceptable salt th...
|
|
WO/2024/077078A2 |
The present invention provides a method of inhibiting growth of a fungus in a subject, comprising reducing the activity of sterylglucosidase I (SigIl) and/or sterylglucosidase A (SglA) in the fungus.
|
|
WO/2024/077087A2 |
The present technology relates generally to compounds for inhibiting M24B aminopeptidases to selectively activating the CARDS inflammasome, an innate immune signaling platform that triggers pyroptotic cell death.
|
|
WO/2024/065043A1 |
Provided are lipids and nanoparticles containing such lipids and a cargo molecule, such as nucleic acid, methods to formulate said lipids with nucleic acids to produce lipid nanoparticles and chemical routes for making the lipids. The li...
|
|
WO/2024/067304A1 |
The present invention provides a compound with inhibitory activity against Sigma2 and 5HT2A. The compound can be used as a dual-target inhibitor of Sigma2 and 5HT2A for the treatment of a related disease mediated by Sigma2 receptor activ...
|
|
WO/2024/067844A1 |
The present application provides a crystal A of fexuprazan hydrochloride. An X-ray powder diffraction pattern thereof has characteristic peaks at positions of 2θvalues of 9.1±0.2°, 13.7±0.2°, 14.9±0.2° and 18.3±0.2°, and has a c...
|
|
WO/2024/067783A1 |
Provided are a compound represented by formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and use of the compound as an androgen receptor (AR) inhibitor.
|
|
WO/2024/067708A1 |
Provided are an ammonium oxalate compound represented by formula (I) or a pharmaceutically acceptable salt, an ester, an optical isomer, a tautomer, a stereoisomer, a polymorph, a solvate, a N-oxide, an isotopically labeled compound, a m...
|
|
WO/2024/072930A1 |
D3R selective partial agonists and their use in treating substance use disorders alone or in combination with affective disorders are disclosed. These substance use disorders include psychostimulant use disorder (PSUD). Compounds include...
|
|
WO/2024/061348A1 |
The present invention provides a 1,3-cyclohexanedione compound shown in formula I, and a stereoisomer and an agrochemically acceptable salt thereof, wherein R1, R2, R3, and R4 are as defined in the description. Also disclosed are a prepa...
|
|
WO/2024/060356A1 |
The present invention relates to an economical and feasible method for industrially producing a deuterated COVID-19 medicament key intermediate D. The method has low reaction line cost, and high conversion rate, selectivity, reaction yie...
|
|
WO/2024/059951A1 |
This invention provides compound having a structure of Formulas I-VI. Uses of such compounds for treatment of various indications that would benefit from modulation of the androgen receptor, including prostate cancer. Also provided are m...
|
|
WO/2024/062310A1 |
The present invention provides derivatives of (2S,3R,4R,5S,6R)-2-[4- chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]-phenyl]-6-(
hydroxymethyl)- oxan-3,4,5-triol (empagliflozin) and (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl...
|
|
WO/2024/059317A1 |
Provided are YAP/TAZ-TEAD oncoproteins inhibitors of Formula (I), or a stereoisomer, and/or a pharmaceutically acceptable salt, and/or solvate thereof, pharmaceutical compositions thereof, and methods of treatment.
|
|
WO/2024/055801A1 |
The present invention relates to a pyridinamide derivative and a use thereof, and specifically relates to a compound of formula (I) or an isotope labeled compound thereof as a pyridinamide derivative, or an optical isomer, a geometric is...
|
|
WO/2024/056101A1 |
The present invention relates to a linker for an antibody-drug conjugate and a use thereof. Specifically, a linker represented by formula I is provided. An antibody-drug conjugate prepared by means of the linker are more stable and more ...
|
|
WO/2024/057249A1 |
The present invention relates to an improved process for the preparation of sulfonylurea based compounds of general formula (I). More specifically present invention provides an improved process for the preparation of compound of formula ...
|
|
WO/2024/057020A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.
|
|
WO/2024/052923A1 |
One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.
|
|
WO/2024/049951A1 |
The disclosure provides methods for treating a human patient with sickle cell disease. These methods include administering a properdin binding antibody or antigen-binding fragment thereof to the patient.
|
|
WO/2024/049979A2 |
Novel ionizable lipids and lipid nanoparticles that can be used in the delivery of therapeutic cargos are disclosed.
|
|
WO/2024/046605A1 |
The compounds of formula (IA) or formula (IB) or a salt thereof. The compounds can be used as reference products in the determination of the administration of ligandrol to a subject.
|
|
WO/2024/045292A1 |
The present invention relates to a method for catalytic industrial production of a deuterated pharmaceutical intermediate D by means of a combination of immobilized nickel and organic alkali. Reaction route conditions are mild, the conve...
|
|
WO/2024/046253A1 |
Provided in the present invention are a sodium channel regulator and the use thereof. The sodium channel regulator of the present invention has a brand-new structure and has an excellent in-vitro inhibitory effect on Nav 1.8. The compoun...
|
|
WO/2024/049236A1 |
The present invention relates to: a method for preparing a chiral gamma lactam derivative or a pharmaceutically acceptable salt thereof by using a chiral organocatalytic compound; and a composition for preventing, alleviating or treating...
|
|
WO/2024/048582A1 |
[Problem] The present invention provides a means which is capable of oxidizing an organic compound in a vapor phase using a nitroxyl radical as a catalyst. [Solution] A catalyst loaded body is obtained by loading a carrier with a compoun...
|
|
WO/2024/044232A1 |
This disclosure relates to compositions and methods useful for selective labeling of compounds containing an N-alkylated imidazole ring. In certain embodiments, this disclosure relates to methods of forming an oxime compound, comprising ...
|
|
WO/2024/044728A1 |
The present disclosure relates to PEGylated lipid compounds and pharmaceutically acceptable salts thereof. Such compounds are useful, for example, as constituent parts of lipid nanoparticle (LNP) formulations for delivery of various acti...
|
|
WO/2024/042119A1 |
There is provided a new and improved synthetic route for the synthesis of the compound 1-{2-[(1R)-1-aminoethyl]-4-chlorobenzyl}-2-thioxo-1,2,3,5-te
trahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one (Formula (I)) that is readily scalable for comm...
|
|
WO/2024/036812A1 |
The present invention relates to the technical field of organic synthesis, in particular to a method for preparing atorvastatin calcium. The method comprises: using 2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)acetonitr
ile as a ra...
|
|
WO/2024/040235A1 |
Provided herein are compounds of formula (A): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, X3, X4, Z1, Z2, Z3, Z4, Ra, Rb, Rc, Rd, Re, L, Y, and m are as defined he...
|
|
WO/2024/034746A1 |
The present invention relates to a method for producing a chiral carbonyl derivative using an (R,R)-1,2-diphenylethylenediamine (DPEN)-based thiourea catalyst compound. According to the production method, a chiral carbonyl derivative hav...
|
